BICO company Biosero signs agreement to develop laboratory automation solutions to a value of 28 MUSD

Published: 8-Dec-2023
Research & Development

Biosero, a BICO company and developer of laboratory automation solutions to orchestrate scientific discoveries, has signed an agreement with a global life science company for a total value of 28 MUSD to design and build an automated R&D, hardware and software platform which consists of 5 sub-projects

The project is estimated to run from late Q4 2023 until Q1 2026 and the platform is aimed to shorten time for drug development workflows. The project will run in a ramp-up phase during 2024 and the vast majority of the project will be carried out and invoiced during 2025.
 
“This agreement is a milestone for the Group and it’s our largest project to date. It also shows the strength in Biosero’s offering for laboratory automation solutions and we expect to shorten current timelines for drug development through automation”, says Maria Forss, President and CEO, BICO.

See more

You may also like

Manufacturing

Exploring Ireland’s thriving life sciences sector

Read more
NSF highlights its pivotal role in one of the world’s leading hubs for pharma and medical device manufacturing

Trending Articles

  1. Bath scientists design peptide "switch" that keeps Parkinson’s protein in its healthy form Researchers at the University of Bath, in collaboration with the Universities of Oxford and Bristol, have developed a molecule that prevents the clumping and build-up of a protein linked to Parkinson’s disease and related dementias
  2. Novartis secures FDA approval for Rhapsido, the first oral BTKi treatment for chronic spontaneous urticaria Rhapsido (remibrutinib) offers a new targeted option for CSU patients, showing rapid symptom control and a favourable safety profile without lab monitoring, as Novartis expands its immunology portfolio
  3. Veraxa and Secarna Pharmaceuticals partner to advance AOC therapies for immune diseases The pair will develop next-generation antibody oligonucleotide conjugates (AOCs) with the aim of unlocking novel targeted therapies for the treatment of autoimmune and chronic immune diseases
  4. Designing and developing bioconjugates for clinical success Abzena shares new insights and technologies to accelerate safe and effective ADC development
  5. Kindeva to showcase complex drug delivery expertise at CPHI 2025 Global CDMO highlights sterile injectable, pulmonary, nasal and dermal capabilities

Upcoming event

CPHI Frankfurt 2025

28–30 October 2025 | Exhibition | Frankfurt, Germany See all

You may also like

Manufacturing

Exploring Ireland’s thriving life sciences sector

NSF highlights its pivotal role in one of the world’s leading hubs for pharma and medical device manufacturing
Manufacturing

Intertronics releases white paper on process validation for medical device bonding

The new guidance helps manufacturers cut costs, save time and ensure ISO and FDA compliance by designing out variability and improving process reliability from the start
Regulatory

FDA lifts clinical hold on Neurizon’s NUZ-001 for ALS trial entry

The decision clears the path for NUZ-001 to join the HEALEY ALS Platform Trial later this year, advancing Neurizon’s lead therapy for amyotrophic lateral sclerosis and strengthening its regulatory and development pipeline
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Building resilient outsourcing strategies: safeguarding oncology research samples against disaster risk (part II)

Part II of this article focuses on defining what “good” looks like in biorepository infrastructure, validation and documentation, providing practical guidance to create resilient, compliant storage solutions that underpin successful oncology research
Research & Development

Daiichi Sankyo launches third global research institute in San Diego

The company expands its international research footprint with a new San Diego institute, strengthening collaborations in one of the world’s leading life-science hubs and advancing its global drug discovery strategy
Research & Development

Bath scientists design peptide "switch" that keeps Parkinson’s protein in its healthy form

Researchers at the University of Bath, in collaboration with the Universities of Oxford and Bristol, have developed a molecule that prevents the clumping and build-up of a protein linked to Parkinson’s disease and related dementias
Manufacturing

Designing and developing bioconjugates for clinical success

Abzena shares new insights and technologies to accelerate safe and effective ADC development
Subscribe now